nach oben

Neurological Sciences

Erschienen in:

03.02.2021 | COVID-19 | COVID-19 Zur Zeit gratis

Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide

verfasst von: Mehmet Fatih Yetkin, Nur Aleyna Yetkin, Merve Akcakoyunlu, Meral Mirza

Erschienen in: Neurological Sciences | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

In December 2019, coronavirus disease 2019 (COVID-19) emerged in Wuhan and rapidly spread throughout China. Since the outbreak of the pandemic, in addition to the well-known COVID-19 symptoms, various neurological symptoms have been also described in patients with COVID-19. Here, we report an unusual presentation of COVID-19 infection in a teriflunomide-treated individual with multiple sclerosis (MS) who did not interrupt teriflunomide treatment during the infection. The course of the infection was mild in this case as in other reported teriflunomide-treated individuals with COVID-19. COVID-19’s presentation may be unusual in people with MS (pwMS). It can also be concluded that teriflunomide may be considered a safe disease-modifying treatment option during the pandemic.

Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y (2020) The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 55(5):105955CrossRef

Asadi-Pooya AA, Simani L (2020) Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci 413:116832CrossRef

Montalvan V, Lee J, Bueso T, de Toledo J, Rivas K (2020) Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin Neurol Neurosurg 194:105921CrossRef

Manji H, Carr AS, Brownlee WJ, Lunn MP (2020) Neurology in the time of COVID-19. J Neurol Neurosurg Psychiatry 91(6):568–570CrossRef

Sepehrinezhad A, Shahbazi A, Negah SS (2020) COVID-19 virus may have neuroinvasive potential and cause neurological complications: a perspective review. J Neuro-Oncol 26(3):324–329

Karussis D (2014) The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun 48-49:134–142CrossRef

Maghzi AH et al (2020) COVID-19 in teriflunomide-treated patients with multiple sclerosis. J Neurol:1–7

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173CrossRef

Jain A, Rosso M, Santoro JD (2020) Wilhelm Uhthoff and Uhthoff’s phenomenon. Mult Scler 26(13):1790–1796CrossRef

10.

Park K, Tanaka K, Tanaka M (2014) Uhthoff’s phenomenon in multiple sclerosis and neuromyelitis optica. Eur Neurol 72(3–4):153–156CrossRef

11.

Davion JB, Lopes R, Drumez É, Labreuche J, Hadhoum N, Lannoy J, Vermersch P, Pruvo JP, Leclerc X, Zéphir H, Outteryck O (2020) Asymptomatic optic nerve lesions: an underestimated cause of silent retinal atrophy in MS. Neurology 94(23):e2468–e2478CrossRef

12.

Boziki MK, Mentis AA, Shumilina M, Makshakov G, Evdoshenko E, Grigoriadis N (2020) COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination. Brain Sci 10(6):345CrossRef

13.

Kalincik T (2015) Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review. Neuroepidemiology 44(4):199–214CrossRef

14.

Hamdy SM, Abdel-Naseer M, Shehata HS, Hassan A, Elmazny A, Shalaby NM, Abokrysha NT, Kishk NA, Nada MAF, Ahmed SM, Hegazy MI, Mekkawy D, Mourad HS, Abdelalim A, Berger T (2020) Managing disease-modifying therapies and breakthrough activity in multiple sclerosis patients during the COVID-19 pandemic: toward an optimized approach. Ther Clin Risk Manag 16:651–662CrossRef

15.

Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H (2014) Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 74(6):659–674CrossRef

16.

Comi G, Miller AE, Benamor M, Truffinet P, Poole EM, Freedman MS (2020) Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: pooled analysis of clinical trials. Mult Scler 26(9):1083–1092CrossRef

17.

Mantero V, Baroncini D, Balgera R, Guaschino C, Basilico P, Annovazzi P, Zaffaroni M, Salmaggi A, Cordano C. Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis. J Neurol. https://doi.org/10.1007/s00415-020-10196-9

18.

Möhn N et al (2020) Mild COVID-19 symptoms despite treatment with teriflunomide and hi3gh-dose methylprednisolone due to multiple sclerosis relapse. J Neurol 1–3

Titel: Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide
verfasst von: Mehmet Fatih Yetkin
Nur Aleyna Yetkin
Merve Akcakoyunlu
Meral Mirza
Publikationsdatum: 03.02.2021
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Neurological Sciences / Ausgabe 5/2021
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-021-05097-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

Dual diagnosis in a child with familial SCN8A-related encephalopathy complicated by a 1p13.2 deletion involving NRAS gene

A novel nonsense mutation in the TYMP gene causing MNGIE with multiple intracranial hemorrhages on brain MRI

Cough syncope and hyperventilation-induced convulsion in Chiari 1.5 malformation

Efficacy of platelet-rich plasma in the treatment of hemiplegic shoulder pain

Static magnetic stimulation in the central nervous system: a systematic review

Selective cranial multineuritis in severe COVID-19 pneumonia: two cases and literature review

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie